Aptamer Group to host webinar and Q&A session for investors

Aptamer Group

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research.

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform,

    Search

    Search